We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BioPharmX

News List

BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 americanpharmaceuticalreview
June 26, 2019
BioPharmX announced positive results from its Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.
BioPharmX Announces Patent Award americanpharmaceuticalreview
August 10, 2018
BioPharmX announced the U.S. Patent and Trademark Office has granted a fifth patent to the company.
U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Top biospace
March 21, 2018
BioPharmX Corporation announced today that the U.S. Patent and Trademark Office granted the company's first patent
BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans americanpharmaceuticacreview
November 09, 2017
Consistent with oral minocycline products, BPX-01 is intended for the targeted treatment of non-nodular inflammatory acne vulgaris.
BioPharmX Invited to Present at World Preclinical Congress biospectrumasia
June 19, 2017
The company presented results of a three arm preclinical study comparing BPX-01 topical hydrophilic formulation of minocycline, lipophilic minocycline formulation and oral minocyline.